MeiraGTx Holdings plc's latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026The company raised major funds to develop gene therapies, showing investors believe in its pipeline.
Board elections determine who oversees the company's strategy and spending decisions.
Quarterly earnings show whether the company is on track with its operations and cash burn.
Partnering with Hologen helps develop Parkinson's and obesity treatments, reducing costs and risk.
New shares dilute ownership but give cash to fund clinical trials and drug launches.
BofA and Goldman underwrite the stock sale, funding operations through 2028 if drugs approved.
Stocky reads MeiraGTx Holdings plc's official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
MeiraGTx Holdings plc's most recent tracked filing was a 8-K on 7 Jul 2026: Secured $375 million royalty note financing from Oberland Capital.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.